|

Chidamide Clinical Trials

20 actively recruiting trials

▲ +1 trial since June 2026

Also known as: Anastrozole, CS055, Epidaza, Fulvestrant, HBI-8000 +5 more

Pipeline

Phase 2: 13Phase 3: 2Phase 1/2: 3

Top Sponsors

  • Tianjin Medical University Cancer Institute and Hospital3
  • Institute of Hematology & Blood Diseases Hospital, China3
  • The First Affiliated Hospital of Soochow University2
  • Ou Bai, MD/PHD2
  • Zhujiang Hospital1

Indications

  • Cancer20
  • Peripheral T Cell Lymphoma3
  • Diffuse Large B-cell Lymphoma(DLBCL)3
  • Leukemia, Myeloid, Acute2
  • Acute Myeloid Leukemia2

Other20 trials

A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19)
Phase 3
A Study of Chidamide Plus Endocrine in Maintenance Treatment of HR+/HER2- Breast Cancer After First-line Chemotherapy
N/A
CRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCL
Phase 2
Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCL
Phase 2
Chidamide Maintenance for MRD-Positive Double-Expressor DLBCL in First Complete Remission
Phase 2
Chidamide Prevents Recurrence of High-risk AML After Allo-HSCT
Phase 1/2
Chidamide for Maintenance Treatment of HBV-infected Diffuse DLBCL in Patients Initially Treated With R-CHOP
Phase 3
Chidamide in Combination With Azacitidine, Liposomal Mitoxantrone, and Prednisone (CAMP Regimen) for the Treatment of Previously Untreated Nodal TFH Cell Lymphoma
Phase 2
Chidamide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (R/R PTCL)
Phase 2
Chidamide, Venetoclax, and Azacitidine for Newly Diagnosed Acute Myeloid Leukemia
N/A
Chidamide/Everolimus for PIK3CA Wild-type/Mutant HR+/HER2- Advanced Breast Cancer
Phase 2
Golidocitinib Combined With Mitoxantrone Hydrochloride Liposome or Chidamide in the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma
Phase 1/2
Post-transplantation Maintenance Therapy With Cidabenamide in Patients With Intermediate/High-risk AML
Phase 2
Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion
Phase 2
QL1706 Plus Chidamide, AG as First-line Treatment for Metastatic Pancreatic Cancer
Phase 2
Randomized Study of ABC-14 Regimen Compared With "3+7" Standard Induction Therapy or AB-14 for ND AML
Phase 2
Safety and Efficacy of Fruquintinib Plus Chidamide and Sintilimab in the Third and Later Line Treatment of MSS/pMMR Metastatic Colorectal Cancer
Phase 2
Single Arm Study of Post-transplant Azacitidine and Chidamide for Prevention of Acute Myelogenous Leukemia Relapse
Phase 1/2
Venetoclax Combined With Azacitidine, Chidamide, Vindesine, and Dexamethasone in Newly Diagnosed ETP-ALL Like Patients
Phase 2
Venetoclax and Azacitidine Combined With Chidamide (VAC) for the Treatment of Newly Diagnosed Acute Monocytic Leukemia
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.